Auctus Biologics

company

About

Auctus Biologics is a biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$228.69K
Industries
Biotechnology,Medical
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.Antibodies are the most prolific biologics in clinical environments because of their ability to bind targets with high affinity and specificity. However, antibodies also carry liabilities. They are often unstable and require costly cold-chain management to reach their destinations in active form. Because of their fragility, antibodies typically cannot be used in extreme environments like the gastrointestinal tract and can require lengthy infusions to administer to patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.72M
Auctus Biologics has raised a total of $1.72M in funding over 2 rounds. Their latest funding was raised on Feb 9, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 9, 2022 Grant $228.69K 1 National Science Foundation Detail
Sep 24, 2018 Seed $1.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Auctus Biologics is funded by 2 investors. National Science Foundation and Grapeseed.Bio are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant
Grapeseed.Bio Seed